Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

被引:0
作者
Hans F Schoellhammer
Felicia Hsu
Courtney Vito
Peiguo Chu
Jinha Park
James Waisman
Joseph Kim
机构
[1] City of Hope Comprehensive Cancer Center,Division of Surgical Oncology, Department of Surgery
[2] City of Hope Comprehensive Cancer Center,Department of Pathology
[3] City of Hope Comprehensive Cancer Center,Department of Radiology
[4] City of Hope Comprehensive Cancer Center,Department of Medical Oncology and Experimental Therapeutics Research
来源
BMC Cancer | / 14卷
关键词
HER2-positive breast cancer; Targeted therapy; Breast cancer liver metastases; Trastuzumab; Pertuzumab; Complete pathologic response;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 214 条
[1]  
Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New England J Med 344 783-792
[2]  
Leyland-Jones B(2006)Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor Ann Surg Oncol 13 776-782
[3]  
Shak S(2006)Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis J Clin Oncol 24 2743-2749
[4]  
Fuchs H(2013)Breast cancer, version 3.2013: featured updates to the NCCN guidelines J Natl Compr Canc Netw 11 753-760
[5]  
Paton V(2013)Predictors of early distant metastasis in women with breast cancer J Cancer Res Clin Oncol 139 645-652
[6]  
Bajamonde A(2013)Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature J Cancer Res Clin Oncol 139 1317-1325
[7]  
Fleming T(2000)Liver metastases from breast cancer: long-term survival after curative resection Surgery 127 383-389
[8]  
Eiermann W(2009)The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320-368
[9]  
Wolter J(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-244
[10]  
Pegram M(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer New England J Med 353 1673-1684